Suggested remit: To appraise the clinical and cost effectiveness of faricimab within its marketing authorisation for treating macular oedema secondary to retinal vein occlusion.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
Cost Comparison Standard
|
| ID number |
6197
|
Provisional Schedule
| Expected publication |
14 August 2024 |
Project Team
| Project lead |
Louise Jafferally |
Email enquiries
| External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors |
Roche (faricimab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Macular Society |
| Professional groups |
Royal College of Physicians |
| Associated public health groups |
None |
| Comparator companies |
AbbVie (dexamethasone intravitreal implant) (confidentiality agreement signed, participating) |
| |
Bayer (aflibercept) (confidentiality agreement signed, participating) |
| |
Biogen Biosimilars (ranibizumab) (confidentiality agreement not signed, not participating) |
| |
Genus Pharmaceuticals (ranibizumab) (confidentiality agreement not signed, not participating) |
| |
Novartis (ranibizumab) (confidentiality agreement not signed, not participating) |
| |
Teva UK (ranibizumab) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
None |
|
Date
|
Update
|
|
08 February 2024
|
Invitation to participate |
|
18 September 2023 - 16 October 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6197 |
|
23 December 2022
|
In progress. DHSC referral received |
|
22 September 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual